Cargando…

Small molecular inhibitors for KRAS-mutant cancers

Three rat sarcoma (RAS) gene isoforms, KRAS, NRAS, and HRAS, constitute the most mutated family of small GTPases in cancer. While the development of targeted immunotherapies has led to a substantial improvement in the overall survival of patients with non-KRAS-mutant cancer, patients with RAS-mutant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xuan, Song, Wenping, Cheng, Cheng, Liu, Ziyang, Li, Xiang, Cui, Yu, Gao, Yao, Li, Ding
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470052/ https://www.ncbi.nlm.nih.gov/pubmed/37662925 http://dx.doi.org/10.3389/fimmu.2023.1223433

Ejemplares similares

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials
por: Chen, Wei, et al.
Publicado: (2022)

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia
por: Li, Ding, et al.
Publicado: (2023)

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer
por: Hammoudeh, Sarah Musa, et al.
Publicado: (2020)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
por: Zhou, Xile, et al.
Publicado: (2023)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
por: Jie, Chen, et al.
Publicado: (2023)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
por: Chao, Yi-Chun, et al.
Publicado: (2021)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis
por: Weng, Ching-Chieh, et al.
Publicado: (2018)

Identification and validation of a prognostic-related mutant gene DNAH5 for hepatocellular carcinoma
por: Song, Zebing, et al.
Publicado: (2023)

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
por: Wang, Haiyun, et al.
Publicado: (2019)

Molecular docking analysis of KRAS inhibitors for cancer management
por: J. Hakeem, Israa, et al.
Publicado: (2023)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report
por: Li, Ding, et al.
Publicado: (2021)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model
por: Wang, Lei, et al.
Publicado: (2022)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Characterization of KRAS Mutational Regression in Oligometastatic Patients
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
por: Xie, Chun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jka37cgt3m3o6hcij56hfv8qgg